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1. Introduction 
The global impact of the human immunodeficiency virus (HIV) pandemic is enormous. To 
date, more than 25 million lives have been claimed by the acquired immunodeficiency 
syndrome (AIDS) and over 33 million people are currently estimated to be HIV-infected. 
Ninety-five percent of these people infected with HIV live in developing countries. Sub-
Saharan Africa is the region that is hit hardest by the HIV pandemic.  
During the quarter century since the first reports of a novel immunodeficiency syndrome in 
1981, great advances have been made in HIV diagnosis, prevention and care. The first 
protease inhibitor (PI) was approved in 1996, marking the start of the highly active 
antiretroviral therapy (HAART) era. From then on, HIV-infections were no longer inevitably 
associated with AIDS and death, but could be viewed as a chronic condition [Merson, 2006; 
Sepkowitz, 2006]. Currently, the antiretroviral armamentarium includes over 20 different 
drugs and more are in the pipeline. The use of HAART can result in effective, long-term 
suppression of the virus with consequent recovery of the patient’s immune system. 
Unfortunately, complete HIV eradication is still not feasible. Moreover, it is apparent that 
the virus generally resurges to pre-treatment levels within months after ART withdrawal. 
Patients therefore need a life-long commitment to their treatment.  
The logistic and monetary costs associated with such long-term HIV-care are high. HIV 
monitoring and treatment was therefore initially only available in resource-rich countries. 
Great efforts and large funds were needed to make ART more widely available. This 
awareness and initiatives, such as the “United States’ President’s Emergency Plan for AIDS 
Relief” and the “Global fund for AIDS, TB and Malaria”, resulted in an unprecedented roll-
out of treatment since the turn of the millennium [United Nations]. The increase in HIV-
infected individuals receiving ART has been especially large In Sub-Saharan Africa where 
over the last decade, many ART programs took off, treating millions of HIV-infected 
patients. Despite these impressive accomplishments however, monitoring and research 
facilities in low-income countries (LICs) still lag behind.  
There are great differences between HIV care in resource-rich and LICs. First, due to limited 
resources, the number of clinics, health care providers and other necessities for quality 
health care are lower in LICs compared to high-income countries. Second, HIV is generally 
transmitted via heterosexual contact in African countries, whereas homosexual contacts and 
intravenous drug use are the main routes of transmission in western countries. Moreover, 
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due to differences in genetic make up there may be different reactions to the virus and its 
treatment between different populations. Third, the virus itself differs between various 
geographical areas. While subtype B is the main HIV subtype in Europe and the United States, 
it is rarely seen in Sub-Saharan Africa, where subtype C is the prevailing HIV subtype. 
The on-treatment HIV-RNA-level is associated with a patients’ clinical outcome. Therefore, 
western guidelines recommend regular HIV-RNA monitoring in all patients receiving ART. 
Roll-out strategies in LICs on the other hand were initially mainly focused on providing as 
many patients with antiretroviral drugs (ARVs) as possible, thereby limiting the resources 
left for laboratory monitoring. As regular HIV-RNA testing is not feasible in many, Sub-
Saharan African ART programs, treatment decisions are frequently solely based on clinical 
or immunological parameters. However, the correlation between these parameters and 
virological outcomes appears to be marginal [Kantor et al., 2009; Keiser et al., 2009; Reynolds 
et al., 2009b]. Moreover, making predictions on long-term treatment outcomes is difficult, as 
the virological effects of these programs are not clear and other surrogate markers for 
clinical outcomes are not available. 
Despite the above mentioned difficulties, great progress has been made regarding HIV care 
in Sub-Sahara Africa. However, challenges remain. Both successes and challenges regarding 
prevention and treatment of HIV as well as viral resistance development and treatment of 
co-morbidities will be addressed in the following chapter.  
2. Prevention 
In 2007, the WHO announced that the HIV-epidemic seemed to be levelling off. Still, over 33 
million people are estimated to be HIV-infected globally, with 2.6 million people becoming 
newly infected annually. The overall adult HIV prevalence in Sub-Saharan Africa is 
estimated to be over five percent, with prevalence rates up to twenty-five percent in some 
countries [UNAIDS, 2009]. This however means that the vast majority (more than ninety 
percent) is still HIV-negative. Keeping these people free from HIV, as well as preventing 
new generations from becoming infected, is a major challenge and should remain a priority 
on the HIV-care agenda.  
2.1 Prevention of mother to child transmission 
One of the great advances in HIV preventive-care has been the “prevention of mother to 
child transmission” (PMTCT) strategies. Testing pregnant women for the presence of HIV 
and subsequently providing those that are infected, as well as their new-born babies, with 
ARVs has the potential of reducing vertical HIV transmission rates to below one percent 
[Paintsil and Andiman, 2007; Paintsil and Andiman, 2009]. Short-course ARVs or single-
dose nevirapine (SDNVP) are frequently used for PMTCT instead of complete ART 
regimens in low-income countries (LICs). Such regimens have shown to be efficacious in 
averting many infant-HIV infections. Still, with transmission rates ranging from one to 
above ten percent, results are lagging behind those observed in resource-rich settings [Boeke 
and Jackson, 2008; Chigwedere et al., 2008; Leroy et al., 2008; Palombi et al., 2007; Tonwe-
Gold et al., 2007]. Moreover, administration of SDNVP can lead to the selection of non-
nucleoside reverse transcriptase- (NNRTI-) associated resistance mutations. There is 
evidence that fewer mutations are selected when other ARVs are added to the SDNVP 
[Arrive et al., 2007; Chi et al., 2007a]. However, the optimal combination of drugs and best 
time for treatment initiation in order to create a feasible and effective PMTCT strategy for 
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LICs, still need to be defined [Chi et al., 2007b; Lockman et al., 2007]. In addition to 
improving the efficacy of PMTCT programmes, the PMTCT coverage needs to be expanded. 
Many resource-limited countries still have a limited PMTCT-coverage; in South Africa for 
example only sixty percent of HIV-infected pregnant women have access to this simple, 
cost-effective strategy and figures are worse for several other LICs [Abdool Karim et al., 
2009; Paintsil and Andiman, 2009]. These data show that, even though much progress is 
made in the field of PMTCT, improvements are urgently needed to prevent even more 
infant-HIV infections and deaths. 
2.2 Vaccines 
Historically, vaccine development is one of the fields in health care where major progress is 
achieved. Many infectious diseases were effectively prevented and some nearly eradicated. 
Unfortunately, results of HIV vaccine research are unrelentingly negative. Many candidate 
vaccines were developed, but the results proved unsatisfactory and major vaccination 
studies were stopped [Johnston and Fauci, 2008]. Despite these failures, some vaccines are 
still being tested. Most of these are directed at stimulating the immune system [Fauci et al., 
2008]. Still, finding an effective vaccine in the near future does not seem likely.  
2.3 Circumcision 
Several other preventive strategies were analyzed and implemented, resulting in variable 
success rates. Male circumcision was put forward to prevent heterosexual HIV transmission 
since a lower female HIV prevalence was observed in Sub-Saharan African countries with 
high levels of male circumcision [Auvert et al., 2005; Williams et al., 2006]. However, 
epidemiological evidence of a direct protective effect of male circumcision on women 
becoming infected with HIV is limited according to some [Weiss et al., 2009]. To date, most 
consider male circumcision to have a significant, albeit partial, efficacy in reducing 
heterosexual HIV transmission [Doyle et al.; Smith et al.]. To what extend expanding 
circumcision coverage will contribute to combating the global HIV epidemic, still needs to 
be determined. 
2.4 Post- and pre-exposure prophylaxis 
Post-exposure prophylaxis (PEP) is a successful prevention method after incidental needle 
or sex accidents. In Sub-Saharan Africa however, where heterosexual contact drives the HIV 
epidemic, PEP provision is limited and will not substantially influence the HIV statistics. 
Pre-exposure prophylaxis (PrEP) on the other hand may prove to be a promising strategy. 
An effective agent that can be used safely by women prior to sexual intercourse and without 
the need for agreement from a partner would be a major contributor to preventive HIV care 
[Al-Jabri and Alenzi, 2009]. However, until now trials of microbicide candidates have shown 
disappointing results; some even suggested a boosted risk of infection as more vaginal 
lesions were observed in treated patients [Al-Jabri and Alenzi, 2009; Wilson et al., 2008]. 
Possibly gels that incorporate ARVs will be more effective as PrEP. Studies are being set up 
and hopefully results will come available in the coming years [Grant et al., 2008].  
2.5 Antiretroviral treatment as a preventive measure 
In spite of these preventive strategies it is not likely that the high HIV incidence will change 
in the near future. Some strategies are only partly effective and many remain grossly 
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underused [USAID, UNAIDS, WHO, CDC and the POLICY project; Kerr et al.]. More 
importantly, the development of a preventive vaccine seems to be nearly impossible and 
HIV-eradication can not be realised with current treatment strategies. Still, provision of ART 
surpasses the obvious benefits it has on an individual level. Treating HIV can be used as an 
essential part of prevention efforts. For heterosexual contact and for mother-to-child-
transmission a clear dose-response effect was found between HIV-RNA levels and risk of 
HIV transmission [Fang et al., 1995; Quinn et al., 2000; Tovanabutra et al., 2002]. As these are 
the main routes of HIV transmission in Sub-Saharan Africa, it seems likely that bringing 
down individual HIV-RNA levels can make a substantial contribution to reducing the 
number of new infections. Indeed, such positive effects were described previously, 
suggesting cost-saving effects of ART due to the reduction of HIV transmission, in addition 
to the clear benefits of such treatment on an individual basis [Granich et al., 2009; Mayer and 
Venkatesh; Montaner et al., 2006]. Up till now, the roll-out of ART has not clearly reduced 
HIV-incidence. If a preventive effect of ART becomes more apparent as treatment-coverage 
increases, and as patients receive care for longer periods of time, will largely depend on the 
number of patients experiencing virological failure.   
2.6 Awareness 
Creating awareness about the risks of unprotected sex and other potential transmission 
routes, as well as providing information on advances that have been made in HIV care, is of 
utmost importance in reducing the stigma’s associated with HIV and in motivating people 
to do an HIV-test. An elevated level of awareness may lead to patients seeking care at a less 
advanced stage of disease. As a result, chances of a good clinical response to ART will be 
greater. Moreover, the period that patients will have high viral loads and therefore are 
highly infectious, will be shorter if patients have their HIV tested and treated at an earlier 
stage. Continued monitoring of HIV incidence, and possibly mathematical modelling 
studies, are needed to further calculate the preventive and cost-saving effects of ART 
expansion programmes. 
3. Treatment 
HIV leads to AIDS and death when left untreated. ART provides clear benefits for those 
infected and rendered HIV-infection a manageable chronic condition. Access to treatment 
increased considerably over the last decade. Still, by the end of 2008, less than half of the 
people in need of treatment in Sub-Saharan Africa actually received ART [UNAIDS 2009] 
and the United Nations endorsed target of “universal access by 2010” has not been met 
[WHO, 2006b]. It was recognized that access to treatment is especially limited for certain 
groups of people, such as those living in rural settings [Crowley et al., 2009]. Therefore, 
continued efforts are needed to increase the availability of ART even further.  
3.1 When to start ART 
When to start ART in HIV-infected individuals remains a controversial issue. Initially, 
treatment was deferred until CD4 counts dropped to below 200 cells/mm3 in most LICs 
[Wood et al., 2005]. In western settings it is common practice to initiate ART earlier, when 
CD4 counts are less than 350 or even 500 cells/mm3, as various studies suggest improved 
treatment outcomes at higher CD4 thresholds [Braithwaite et al., 2008; Emery et al., 2008; 
Kitahata; Sterne]. Benefits of an earlier treatment start may be even greater in LICs 
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compared to high-income countries, due to higher rates of opportunistic diseases and 
mortality there. However, the number of people eligible for ART will increase as CD4 
treatment-initiation thresholds move up, putting extra pressure on the already fragile health 
care facilities and limited resources. A mathematical modelling study on the other hand 
reported that an increase of the CD4 treatment-initiation threshold (to 350 cells/mm3) would 
reduce morbidity and mortality while remaining cost-effective, in the South African context 
[Walensky et al., 2009]. Moreover, the WHO recently adjusted its guidelines, recommending 
to start treatment at CD4 counts of 350 cells/mm3 or less for all HIV-infected individuals 
[Crowley et al., 2009]. However, definite results from ongoing, international trials assessing 
when to initiate ART in resource-limited settings will not be available for several years.  
3.2 Treatment outcomes 
Overall, on-treatment, short-term outcomes of Sub-Saharan African ART programs that 
have access to HIV-RNA monitoring, are promising and similar to those initially observed 
in western settings. However, high early attrition (composed of all-cause mortality and 
patients being lost to follow up) is frequently observed, negatively influencing intention-to-
treat results. Within a few years after treatment start, virological failure is observed in only 
fifteen percent of patients. It should be borne in mind though, that applied failure criteria 
are generally more lenient than those used in western settings [Barth RE, 2010b].  Long-term 
outcome data are still limited, but seem promising as well.  
First-line ART regimens in Sub-Saharan Africa are generally NNRTI-based. Boosted PIs may 
also be used in treatment-naïve patients. Compared to an NNRTI-based first-line regimen 
this resulted in a slightly reduced treatment efficacy, but fewer resistance mutations 
[Riddler et al., 2008; von Wyl et al., 2007]. A review on clinical trials also showed that fewer 
nucleoside reverse transcriptase inhibitor- (NRTI)-associated resistance mutations were 
present in case of boosted PI-based regimen failure compared to NNRTI-based regimens 
[Gupta et al., 2008]. The answer to the question whether or not it is advisable to move to a 
PI-based first-line ART regimen in LICs will largely depend on the balance between costs, 
adverse events and resistance development profiles.  
3.3 Adverse effects  
Providing all those in need with ART is a daunting task. However, caring for those already 
receiving treatment poses many challenges as well. As HIV-infected people live longer, the 
long-term effects of the virus and its treatment become more evident. Simple, affordable 
treatment regimens facilitated the initial, extensive ART roll-out. However, the negative 
effects associated with these commonly used treatment options called for a reconsideration 
of widely applied treatment strategies. Mitochondrial toxicity causes neuropathy, 
lipodystrophy and lactic acidosis in many individuals receiving stavudine-containing ART. 
Therefore, it was recommended to move away from stavudine-based regimens to 
zidovudine or tenofovir (TDF) [Crowley et al., 2009; WHO, 2006a]. As yet, not all African 
countries have adopted TDF as a first-line regimen in their guidelines for financial reasons, 
but this may change during coming years. As TDF becomes more widely available, 
knowledge of its side-effects grows more important. TDF has potential nephrotoxic effects. 
Generally no negative effects on renal function are observed when TDF is used in a first-line 
ART regimen [Gallant and Moore, 2009], but little is known regarding the prevalence and 
nature of renal impairment in African cohorts. In one South African cohort the number of 
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people with severe renal dysfunction was limited [Franey et al., 2009], but future studies 
will have to show what the long-term effects of TDF use in African patients are. Another 
concern with TDF use relates to the possible increased risk of bone disease. HIV-infected 
individuals have an increased risk of osteopenia compared to HIV-uninfected people. This 
risk is increased further by the use of TDF [Jacobson et al., 2008]. It is not yet clear whether 
patients receiving TDF also have an increased bone-fracture risk. The increased risk of 
cardiovascular disease and diabetes, associated with some antiretroviral drugs, will be 
discussed in more detail later. These and other negative effects of long-term ARV use in 
various populations have to be addressed in future studies.  
3.4 Second line treatment 
PIs are becoming more widely available in LICs since the advent of heat-stable drug 
formulations. They are typically used in second-line regimens, in case of treatment failure. 
As currently the vast majority of patients receiving ART in Sub-Saharan Africa are receiving 
a NNRTI-based, first-line regimen, limited data are available on the efficacy of PI-based 
regimens in African settings. Good, early, virological responses were reported, but a 
frequent occurrence of adverse events was also observed [Castelnuovo et al., 2009a; 
Hosseinipour et al.]. In a large trial performed in western countries (TITAN trial) over three 
quarters of treatment-experienced patients achieved an HIV-RNA less than 400 copies/mL 
after switching to either lopinavir/ritonavir or darunavir/ritonavir in combination with an 
optimized backbone regimen. Results were even better if patients with any prior PI-
exposure were excluded from analysis [Madruga et al., 2007]. These data suggest that a 
boosted PI-based second-line regimen would be effective in the majority of African patients 
who experience treatment failure while receiving NNRTI-based first-line ART. However, 
the generalisability of these data is limited as defining an optimized backbone is hazardous 
in LICs, where fewer ARVs are available and resistance testing is not widely available. 
Long-term data regarding second-line efficacy in resource-limited settings are not yet 
available and should be a subject for future research.  
3.5 New antiretroviral drugs 
New drugs within traditional drug classes and new drug-classes were developed over the 
last years. In western countries drugs such as boosted darunavir and etravirine as well as 
drug-classes such as fusion and integrase inhibitors, CCR5-receptor antagonists and 
maturation inhibitors expanded the antiretroviral arsenal. Long-term care for HIV-infected 
patients frequently demands switching to third- or consecutive lines of ART. Moreover, an 
individualised- rather than a protocol-based approach is increasingly being used. Viral 
characteristics, such as HIV-subtype and presence of drug-resistance mutations, as well as 
host characteristics such as medical history, organ functions and genetic background, all 
contribute to the efficacy and toxicity of the various ARVs. Most HIV-related 
pharmacological research was done in resource-rich settings, where Caucasian, male 
patients, infected with a subtype-B virus, predominate. Important differences exist between 
western and non-western countries regarding both these viral- as well as these host- 
characteristics. Even though the new ARVs will not shortly become available on a large-
scale in LICs, it will be interesting to analyse what effects such drugs have in different ethnic 
populations and on various HIV-subtypes. Such research hopefully provides more insight in 
the dynamics between drugs, viruses and hosts and increases therapeutic options for all 
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HIV-infected individuals in the future. Moreover, expansion of the ARV armamentarium for 
second- and consecutive- lines of treatment is needed to ensure treatment success in the 
future.  
3.6 Paediatric HIV care 
Ninety percent of the 2.1 million HIV-infected children worldwide live in LICs. Until 
recently it was estimated that few vertically HIV-infected children survived beyond the age 
of five years. However, despite high mortality-rates in HIV-infected infants, a substantial 
increase of older survivors of mother-to-child transmission is visible in Africa [Ferrand et al., 
2009]. Caring for small, HIV-infected children is associated with specific challenges, such as 
drug-administration problems and weight-based dosing. Later, during adolescence, an 
increased fear for stigma and loss of social acceptance may lead to a decreased adherence to 
treatment. Still, paediatric ART can result in virological and immunological benefits which 
are comparable to those observed among children in more developed settings [Ciaranello et 
al., 2009]. Unfortunately, despite optimistic, initial outcomes, long-term paediatric ART is 
associated with frequent virological failure [Barth et al. 2010c]. Similar to adult patients, 
most children were receiving NNRTI-based ART. Paediatric treatment outcomes may 
improve when PI-based regimens are used, which have a higher genetic barrier and are 
therefore somewhat more forgiving in case of sub-optimal treatment adherence. However, 
the effects of a long-term HIV infection and many years of ART on growth and development 
are not yet known. Simplifying treatment regimens and limiting side effects will be crucial 
to retain children in care and achieve good, long-term clinical outcomes.   
4. Drug-resistance development 
First-line ART failure is generally caused by poor adherence to the drugs. Various issues are 
linked to poor adherence. Drug toxicity is a major contributor, but other factors such as co-
morbidities, insufficient drug supply, stigma, pill burden and traditional beliefs can play a 
role in drug-adherence. Contrasting initial fears, observed adherence rates in African ART 
programmes are good [Mills et al., 2006]. Still, around 15 percent of patients receiving first-
line treatment in Sub-Saharan Africa experience virological failure within a few years after 
treatment initiation [Barth RE, 2010b].  
In western guidelines it is recommended to perform resistance testing in case of virological 
failure in order to determine an optimal second-line regimen with a sufficiently high genetic 
barrier. Regular resistance testing is not feasible in most African clinics. In western 
countries, most HIV-infected individuals are infected with HIV-1, subtype B. This is in stark 
contrast with Sub-Saharan African countries, were less than one percent of patients subtype-
B virus. Various non-B subtypes are prevalent, with subtype-C being most prevalent. 
Therefore, treatment outcome data and genotypic resistance data from western studies can 
not simply be extrapolated to African settings. 
Available resistance data of people experiencing virological failure in LICs typically show 
(multiple) NNRTI-associated mutations and the lamivudine-associated M184V mutation 
[Barth RE, 2010b; Barth et al., 2008; Hoffmann et al., 2009; Marconi et al., 2008]. With such 
drug-resistance profiles a PI-based second-line regimen will generally be effective. Actual 
second-line treatment outcomes may however be less good. As in many HIV-treatment 
programmes in LICs regular HIV-RNA testing is not feasible, and due to the delay before 
immunological and clinical decline becomes apparent, there may be a large number of 
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people where virological failure remains unnoticed [Castelnuovo et al., 2009b; Kantor et al., 
2009; Keiser et al., 2009; Reynolds et al., 2009b]. These people will continue their failing, first-
line regimen. This is important, as a delay in treatment modification after virological failure 
is associated with an increased mortality [Petersen et al., 2008]. Moreover, an accumulation 
of drug-resistance mutations is observed in patients who continue first-line ARVs in spite of 
virological failure, limiting future treatment options [Cozzi-Lepri et al., 2007; Hoffmann et 
al., 2009; Reynolds et al., 2009a]. Empirically starting second-line ART in programmes with 
limited access to virological diagnostics, may therefore result in sub-optimal treatment 
outcomes, stressing the need for affordable, easy-access drug-resistance tests in LICs.  
Drug-resistant HIV not only decreases the efficacy of new ART regimens in patients 
harbouring such a virus; transmission of resistant strains in the community may also limit 
first-line treatment outcomes of newly infected individuals [Barth et al., 2008; Kuritzkes et 
al., 2008; Wensing et al., 2005]. Fortunately, transmission of drug-resistant viruses is still 
limited in the African continent. Published primary resistance rates are generally well-below 
the WHO cut-off rate of five percent [Bartolo et al., 2009; Bussmann et al., 2005; Derache et 
al., 2008]. The prevalence of drug-resistant viruses will probably increase in LICs though, as 
ARVs become more widely available in those countries. Regular monitoring of primary 
resistance is needed to predict whether currently used treatment regimens will remain 
effective in the majority of patients.  
5. Co-morbidities 
Many other, both communicable and non-communicable, diseases can cause morbidity and 
mortality in HIV-infected individuals. Diagnosing and treating such co-morbidities are of 
utmost importance when caring for people with HIV. Below, a few of these diseases will be 
briefly addressed. 
5.1 Tuberculosis 
Concomitant with the HIV epidemic, South Africa has one of the worst TB epidemics of the 
world [Abdool Karim et al., 2009; WHO, 2009]. The HIV/TB co-infection rate is estimated to 
be as high as 70%, causing morbidity and mortality in many. However, making a definite TB 
diagnosis is hazardous, especially in HIV-infected individuals. In immuno-compromised 
patients, sputum-smear-negative and non-pulmonary TB are frequent, limiting the utility of 
commonly available TB diagnostics. Culturing mycobacterium tuberculosis, the golden 
standard when making a TB diagnosis, is often omitted due to the time and money needed 
for these tests. Therefore, there is a clear need for accurate, simple and low-cost diagnostic 
tests for the detection of TB infection. 
The use of ART causes a great reduction in the risk of developing TB in the long term [Badri 
et al., 2002]. However, the incidence of TB increases soon after ART initiation, following the 
restoration of immune responses [Bonnet et al., 2006; Lawn et al., 2005; Moore et al., 2007]. 
As a result, TB is an important cause of the high mortality during the first months of ART, 
observed in many HIV treatment programmes [Brinkhof et al., 2007; Koenig et al., 2009; 
Lawn et al., 2008; Manabe et al., 2009]. 
The WHO declared that “urgent and extraordinary means” are needed in order to combat 
this massive disease burden, and it set targets for cure and case detection rates [WHO, 2009]. 
Unfortunately, in South Africa these targets are far from being met. Case detection rates are 
only 62% instead of the WHO minimum target of 70% and cure rates are only 58% instead of 
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the intended 85% [Abdool Karim et al., 2009]. These worrying figures are partly due to the 
expansion of multi- and even extensively- drug-resistant TB (MDR and XDR). Case-fatality 
rates are much higher in case of drug-resistant TB, compared with sensitive mycobacterial 
infections. Exogenous, nosocomial re-infections are thought to drive the spread of drug-
resistant TB. Drug-susceptibility testing is needed to identify those in need of stricter 
isolation and broader anti-tuberculosis treatment regimens. However, susceptibility testing 
is currently only done in a subgroup of re-treatment cases and even if such testing is 
performed, it often takes long before results are available. The development of cheap, fast 
HIV-tests was an important contribution to the massive scaling up of HIV-care. Such easy-
access tests are also needed to make a rapid TB diagnosis and to differentiate drug-resistant 
from normally susceptible infections [Lawn et al.]. Hopefully efforts to optimize diagnostic 
and treatment strategies, combined with a better integration of HIV- and TB-care will 
eventually result in a reversal of the TB epidemic.  
5.2 Hepatitis 
Apart from TB, hepatitis B (HBV) and C (HCV) co-infections are commonly observed in 
HIV-infected individuals. As ART roll-out continues, life expectancy of HIV-infected 
individuals in resource-limited countries improves. As a result, long-term effects of such 
hepatitis co-infections, like liver cirrhosis and hepato-cellular carcinomas, become more 
evident. HBV as well as HCV are highly prevalent in African, HIV-infected individuals (15% 
and 7% respectively’, but there is a wide geographical variation in HBV and HCV 
prevalence [Barth et al. 2010a]. 
In western countries HIV infection is strongly associated with an increased incidence of both 
HBV and HCV [Burnett et al., 2005; Rockstroh et al., 2005; Thio, 2009]. This association is 
attributed to shared routes of transmission: mostly (homo)sexual contact in the case of HBV 
and intravenous drug use (IVDU) for hepatitis C [Cooper et al., 2009; Lavanchy, 2004; Modi 
and Feld, 2007]. In African countries HBV acquisition is assumed to occur during early 
childhood. As the route of HIV transmission in Africa is mainly via heterosexual contact, at a 
later point in life, it can be expected that the association between both infections is limited. 
However, reliable data on the mode and age of HBV acquisition amongst HIV-infected 
individuals in Africa are lacking. The predominant mode of HCV transmission in Africa is not 
yet established. However, IVDU seems to be less influential as in western countries [Cooper et 
al., 2009; Lavanchy, 2004; Modi and Feld, 2007]. Due to the different times and modes of 
transmission, the observed association between HIV and the hepatic viruses is less evident in 
Sub-Saharan Africa. Still, the burden of HIV/hepatitis co-infections in that region is high, as all 
these viruses are highly endemic. According to WHO estimates, 22.5 million HIV-infected 
people lived in Sub-Saharan Africa by the end of 2007 [WHO, 2007]. When geographical 
variations in HBV and HIV prevalence are not taken into account, an HBV prevalence of 15% 
would mean that 3.4 million HBV/HIV co-infected people live in this region. 
HIV accelerates the progression of HBV and HCV related liver disease. Evidence that such 
co-infections are also associated with an increased mortality came available only recently 
[Chen et al., 2009; Nikolopoulos et al., 2009]. It is to be expected that HBV and HCV related 
cirrhosis and malignancies will become even more evident during coming years, as ART 
roll-out carries on and life-expectancy for HIV-individuals improves.  
Knowledge on a patients’ HBV/HCV status can help clinicians interpret clinical problems 
and lab results. More importantly, such information can guide decisions on which ARVs can 
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best be prescribed in co-infected patients. The vast majority of first-line ART regimens in 
Sub-Saharan Africa contain lamivudine. Lamivudine has long been approved for the 
treatment of chronic HBV. However, it has a poor resistance profile. Around half of HBV-
isolates show drug-resistance mutations after 2-3 years of lamivudine use [Liaw et al., 2000; 
Lok et al., 2000]. Tenofovir is not yet widely available in Sub-Saharan Africa, but its use may 
increase during coming years. This nucleotide analogue has been approved for the 
treatment of HBV in 2008. Rates of HBV suppression in mono-infected patients are 
impressive and drug-resistance development seems to be limited [Marcellin et al., 2008]. 
Another problem regarding lamivudine use in HIV/HBV co-infected patients can arise 
when lamivudine is being stopped. A paradoxical HBV ‘flare up’ can occur, potentially 
causing liver tissue destruction [Lim et al., 2002].  
Treating HCV infections is not feasible in most African settings due to the high costs and 
intensive monitoring associated with currently available therapies. Still, knowledge on a 
possible HCV co-infection is useful. Screening policies for liver cirrhosis and hepato-cellular 
carcinomas can be installed and the use of hepato-toxic agents can be minimized.   
5.3 Non-communicable diseases 
The unprecedented increase in ART roll-out which took place over the last decade shows 
what can be achieved with the joined efforts of international organisations, governments, 
non-governmental organisations and many enthusiastic, hard-working people. An extensive 
expansion of health care infrastructures was realized in many countries in order to reach 
and treat the millions of HIV-infected individuals. Large funds were made available to make 
ART free of charge for most patients. After being enrolled in an HIV-treatment programme, 
patients are frequently also provided with other medical care, like the diagnostics for and 
treatment of opportunistic infections. For HIV-negative persons on the other hand, medical 
care is frequently less readily available and costly. This may lead to disparities between 
individuals with HIV and those who are suffering from other (chronic) illnesses. Instead of 
increasing the gap between medical care that is available to HIV-infected and HIV-
uninfected individuals, we should try to extend the benefits of the improved health care 
systems to other target groups. As in the established market economies, non-communicable 
disorders are the leading cause of death in adults in low- and middle-income countries. 
Ischemic heart disease and cerebrovascular accidents are the most frequent causes of death. 
Risk factors such as hypertension, diabetes, smoking and obesity are major contributors to 
this disease burden [Chopra et al., 2009; Gill et al., 2009; Lopez et al., 2006; Murray and 
Lopez, 1997; Sliwa and Mocumbi, 2009]. Sub-Saharan Africa includes countries with the 
highest non-communicable disease burden, such as South Africa. Poor people living in 
urban areas are affected most, but the burden is clearly rising in rural communities [Mayosi 
et al., 2009]. This rise is partly due to demographic changes; people grow older despite the 
negative effect of the HIV epidemic.  
As ART roll-out continues, cardiovascular diseases will become even more evident due to a 
decline in HIV-related mortality. Moreover, an increased incidence of inflammatory 
circulatory disorders is observed in HIV-infected individuals and the use of PIs and certain 
NRTIs is associated with a greater risk of insulin resistance, lipodystrophy and 
dyslipidaemia [Friis-Moller et al., 2007; Grunfeld et al., 2009; Hsue et al., 2009]. Despite these 
worrying figures, attention for the prevention and treatment of non-communicable diseases 
in African countries has been limited because most efforts were directed at combating the 
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HIV and tuberculosis epidemics. However, there is a growing recognition that an integrated 
chronic care model is needed to combat both epidemics of communicable and non-
communicable diseases in Sub-Saharan Africa. Surveillance, treatment and prevention 
strategies need to be improved [Unwin et al., 2001].  
6. Finance 
Over the last decade more funds have been raised to combat the HIV epidemic than have 
ever been made available for a single disease. The above described successes would never 
have been achieved without these funds. However, due to the number of HIV-infected 
people and the chronic nature of the disease, there remains a continued need for large 
amounts of money. Expansion of preventive strategies, earlier and wider access to ART, 
increased availability of laboratory testing, and improved health care facilities for both HIV-
infected and HIV-uninfected individuals are all urgently needed, but costly. HIV-care is 
generally sponsor-based, making it sensitive to global economic instability. Currently, the 
economic crisis, and possibly donor fatigue, are negatively influencing the amount of money 
donors are willing to spend on the worldwide HIV epidemic [Ewing, 1990]. Therefore, using 
the available resources as efficiently as possible is of utmost importance. Prioritizing is 
needed when treatment capacity is limited, but leads to many difficult ethical and 
humanitarian dilemmas. Rather than considering the costs associated with expanding HIV 
care, we should consider the costs of not treating all HIV-infected individuals. A recent 
modelling study argues that by spending the available money wisely, but rapidly, 
eradication of AIDS will be feasible. Holding money in reserve now, could lead to extra, 
unnecessary infections and therefore extra costs in the future [Smith et al., 2009]. Moreover, 
the loss of large numbers of people who are in their working age and the resulting increase 
in HIV-related orphans has an enormous negative impact on economies and future 
generations. Therefore, continued attention and funds are still needed to control the HIV 
epidemic and to hopefully make HIV care more affordable in the future. 
7. Conclusion 
Since the start of the HIV epidemic, much progress has been made regarding global HIV-
care. The joint efforts of people, organisations and governments around the world made it 
possible to reverse a previously fatal disease to a chronic condition and to prevent many 
from becoming newly infected. This is a great accomplishment. Still, the time to “sit back 
and relax” has by no means been reached. As in LICs large-scale ART has only been 
available for a couple of years, the long-term effects of HIV infections and their treatment in 
different groups of people are still unknown. Where initial programmes were mainly 
focussed on treating as many HIV-infected people as possible, future studies need to focus 
on the long-term care. There are important differences, both in host as in viral factors, 
between the western and African HIV epidemics. The long-term treatment effects, adverse 
events and viral resistance profiles in African ART programmes therefore need to be 
analyzed. In addition to the currently available strategies, new preventive methods and 
treatments are under development. Testing their efficacy and making them available in LICs 
should be another focus of future research. Moreover, by extending the focus beyond HIV-
care and trying to improve the care for other important chronic diseases, HIV scale-up may 
generate substantial benefits for the broader health system in many countries. 
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